Table 1 Clinical and laboratory features in 180 patients with 2022 WHO-defined MDS/MPN-SF3B1-T, classified by BM RS percentage.
Variable | All patients with MDS/MPN-SF3B1-T (n = 180) | Patients with BM RS < 15% (n = 24) | Patients with BM RS ≥ 15% (n = 156) | P value |
|---|---|---|---|---|
Males; n (%) | 105 (58.3) | 20 (83.3) | 85 (54.5) | 0.008 |
Age in years; median (IQR) | 65 (57–70) | 67 (61–71) | 65 (57–70) | 0.361 |
WBC × 10E + 9/L; median (IQR) | 5.9 (4.2–8.8) | 6.6 (3.7–9.0) | 6.0 (4.2–8.8) | 0.754 |
ANC × 10E + 9/L; median (IQR) | 3.9 (2.2–5.6) | 4.9 (2.1–6.3) | 3.8 (2.2–5.5) | 0.305 |
Hemoglobin g/dL; median (IQR) | 74 (63–88) | 75 (64–88) | 74 (62–88) | 0.719 |
MCV femtoliter; median (IQR) | Evaluable = 169 | Evaluable = 21 | Evaluable = 148 | |
103.2 (96.5–109.5) | 102.8 (90.4–110.2) | 103.2 (96.5–109.3) | 0.603 | |
Platelets × 10E + 9/L; median (IQR) | 552 (487–718) | 630 (497–755) | 540 (487–710) | 0.176 |
lactic dehydrogenase U/L; median (IQR) | Evaluable = 126 | Evaluable = 19 | Evaluable = 107 | |
216.4 (165.4–261.2) | 300.5 (218.4–343.5) | 204.2 (161.0–252.2) | 0.002 | |
Erythropoietin mIU/ml; median (IQR) | Evaluable = 138 | Evaluable = 22 | Evaluable = 116 | |
248.2 (72.1–758.0) | 586.7 (118.2–760.5) | 212.6 (70.6–747) | 0.422 | |
Blasts in PB %; median (IQR) | 0 (0) | 0 (0) | 0 (0) | 1.000 |
Blasts in BM %; median (IQR) | 0.5 (0–1.0) | 1.0 (0–2.0) | 0.5 (0–1.0) | 0.114 |
BM RS %; median (IQR) | 38 (24–57) | 4 (1–10) | 44 (28–60) | <0.001 |
reticulin fibrosis grade | Evaluable = 161 | Evaluable = 22 | Evaluable = 139 | |
reticulin fibrosis grade ≥ 2; n (%) | 16 (9.9) | 4 (18.2) | 12 (8.6) | 0.314 |
Cytogenetics | Evaluable = 169 | Evaluable = 23 | Evaluable = 146 | |
Abnormal karyotype; n (%) | 34 (20.1) | 3 (13.0) | 31 (21.2) | 0.528 |
Complex karyotype; n (%) | 5 (3.0) | 1 (4.3) | 4 (2.7) | 0.523 |
IPSS-R cytogenetics; n (%) | 0.466 | |||
Very good | 5 (3.0) | 1 (4.3) | 4 (2.7) | |
Good | 132 (78.1) | 18 (78.3) | 114 (78.1) | |
Intermediate | 27 (16.0) | 3 (13.0) | 24 (16.4) | |
Poor | 3 (1.8) | 0 (0) | 3 (2.1) | |
Very poor | 2 (1.2) | 1 (4.3) | 1 (0.7) | |
Abdominal ultrasound | Evaluable = 84 | Evaluable = 8 | Evaluable = 76 | |
Splenomegaly (ultrasound); n (%) | 41 (48.8) | 5 (62.5) | 36 (47.4) | 0.658 |
Next-generation sequencing analysis; n (%) | Evaluable = 122 | Evaluable = 23 | Evaluable = 99 | |
ASXL1-mutated | 21 (17.2) | 3 (13.0) | 18 (18.2) | 0.778 |
CALR-mutated | 0 (0) | 0 (0) | 0 (0) | / |
DNMT3A-mutated | 26 (21.3) | 6 (26.1) | 20 (20.2) | 0.735 |
IDH1-mutated | 1 (0.8) | 0 (0) | 1 (1.0) | 1.000 |
IDH2-mutated | 0 (0) | 0 (0) | 0 (0) | / |
JAK2-mutated | 40 (32.8) | 5 (21.7) | 35 (35.4) | 0.210 |
MPL-mutated | 8 (6.6) | 2 (8.7) | 6 (6.1) | 1.000 |
RUNX1-mutated | 2 (1.6) | 0 (0) | 2 (2.0) | 1.000 |
SETBP1-mutated | 8 (6.6) | 3 (13.0) | 5 (5.1) | 0.354 |
SF3B1-mutated | 114 (93.4) | 23 (100) | 91 (91.9) | 0.346 |
SRSF2-mutated | 6 (4.9) | 3 (13.0) | 3 (3.0) | 0.143 |
TET2-mutated | 36 (29.5) | 4 (17.4) | 32 (32.3) | 0.207 |
TP53-mutated | 10 (8.2) | 4 (17.4) | 6 (6.1) | 0.173 |
U2AF1-mutated | 2 (1.6) | 0 (0) | 2 (2.0) | 1.000 |
Thrombotic event | Evaluable = 100 | Evaluable = 11 | Evaluable = 89 | |
Thrombotic event, at or prior to diagnosis; n (%) | 15 (15) | 3 (27.3) | 12 (13.5) | 0.447 |
Thrombotic event, after diagnosis; n (%) | 4 (4) | 0 (0) | 4 (4.5) | 1.000 |
Leukemic transformations | Evaluable = 126 | Evaluable = 13 | Evaluable = 113 | |
Leukemic transformations; n (%) | 11 (8.7) | 1 (7.7) | 10 (8.8) | 1.000 |
